Introduction {#Sec1}
============

Neonatal haemolytic uremic syndrome (HUS) is characterised by the triad of microangiopathic haemolytic anaemia (MHA), thrombocytopenia and renal failure (Corrigan and Boineau [@CR6]). It is rare in newborns; to be very precise probably under-reported. To our knowledge, only five cases of neonatal HUS have been reported to-date; three were found to be associated with birth asphyxia (Biran et al. [@CR2]), one was associated with transplacental transmission of *E. coli* O157 (Ulinski et al. [@CR13]) and another related to intracellular vitamin B12 deficiency (Kind et al. [@CR9]).

We describe the case of a neonate with HUS secondary to birth asphyxia presenting as severe anaemia, as early as 4 h of life. The anaemia was refractory to red cell transfusions. The haematological and renal profile improved following a double volume exchange transfusion done at 16 h of life. Plasmapheresis and plasma infusions have been used previously to treat HUS. Exchange transfusion essentially provides plasma exchange besides augmenting the haemoglobin levels. Arguably this is the first report of neonatal HUS treated with exchange transfusion.

Case description {#Sec2}
================

A three kilogram baby boy was born vaginally at 38 weeks of gestation to a primiparous mother. The baby was meconium stained and not vigorous at birth. Endotracheal intubation and positive pressure ventilation were needed for resuscitation. He was extubated at 3 min of life, after establishment of adequate respiratory efforts.

Haemoglobin at birth was 18.3 g/dL and the platelet count was 1.62 × 10^9^/L. A blood smear examination done at 1 h of life was normal (Table [1](#Tab1){ref-type="table"}). At around 4 h of life, marked pallor was noted. Respiratory distress (respiratory rate 70/minute), subcostal retractions and falling saturations necessitated initiation of bubble CPAP. CPAP of 8 cm of water and FiO~2~ of 50 % were needed to maintain oxygen saturations above 90 %. Falling blood pressure and other markers (clinical and biochemical) of hemodynamic compromise prompted fluid resuscitation followed by ionotropes. Dobutamine was started to augment the falling cardiac output. Subsequently, oligo-anuria was also noted to have set in.Table 1Table of investigationsParameters (in SI units)Age of the index case (in hours, in the first 72 h) and investigations done1 h of life4 h of life7 h of life14 h of life29 h of life53 h of life65 h of lifeDay 4 of lifeTotal leucocyte counts, TLC (per μL)26,10012,20025,20065006700750011,900Hemoglobin (gm/dL)18.37.76.412.113.112.912.7Hematocrit (in %)57.823.12036.439.339.138.4Platelet count (per μL)162,00043,00064,00070,00080,00089,000108,000Reticulocyte count (in %)5.67.8Direct coomb's testNegativeBlood urea nitrogen (mg/dL)12.040.318.716.210.64.4Creatinine (mg/dL)1.31.61.20.80.60.5Prothrombin time (s)14.8Partial thromboplastin time (s)28.7INR (international normalized ratio)1.05Sodium (mEq/L)145.3137.1145.0136.4138.0143.3Potassium (mEq/L)4.34.13.843.605.115.0Serum total calcium (mg/dL)9.76.16.111.37.09.7Serum total bilirubin (mg/dL)1.728.70Serum indirect bilirubin (mg/dL)1.367.91Creatinine phosphokinase (U/L)1414CK--MB (U/L)96pH7.1817.1537.1987.419CO~2~ (mmHg)43.321.42846.3HCO~3~ (mmol/L)15.67.215.629.5Lactate (mg/dL)8.722.56.81.5Schistocytes in peripheral blood smearPresent (Fig. [1](#Fig1){ref-type="fig"})

The results of the investigations at 4 h are detailed in the Table [1](#Tab1){ref-type="table"}. The haemoglobin had fallen to 7.7 g/dL and platelets had decreased to 43,000/mm^3^. Peripheral smear showed fragmented RBCs and schistocytes suggestive of MHA (Fig. [1](#Fig1){ref-type="fig"}). The baby was switched on to intermittent positive pressure ventilation at 5 h of life in view of worsening respiratory distress. Chest X-ray did not reveal any lung parenchymal abnormality. Packed cells (45 mL) were transfused at 6 h of life, followed by a second transfusion (45 mL) as the haemoglobin did not rise satisfactorily following transfusion of the first aliquot. Haemoglobin remained low (6.7 g/dL) even after two transfusions at 7 h of life. The reticulocyte count was 7.8 %. Blood urea nitrogen was 40.3 mg/dL and serum creatinine was 1.6 mg/dL at 14 h of life. Prothrombin time, partial thromboplastin time and FDP were normal. There was no haematuria and proteinuria or bleeding from peripheral cannulation sites. Ultrasound examination of cranium and abdomen were normal. The blood group of the baby was compatible with the mother's and direct Coombs test was negative. There was no family history of atypical HUS. There were no extra-renal manifestations of birth asphyxia.Fig. 1Peripheral smear showing schistocytes classical of microangiopathic haemolytic anaemia

On account of the falling haemoglobin which continued despite packed cell transfusions, the evidence of red blood cell fragmentocytosis, deranged renal functions and the normal coagulation screen, a diagnosis of neonatal HUS was made. 90 mL of fresh plasma was transfused. A double volume exchange transfusion with whole blood cross-matched with both baby and mother was performed using 480 mL of group A Rh positive blood. Following the exchange transfusion, haemoglobin increased to 13.1 gm/dL, platelet count increased to 80,000/mm^3^, BUN decreased to 18.7 mg/dL, serum creatinine fell to 1.2 mg/dL and urine output improved gradually as well. No further blood transfusions or renal replacement therapy were needed. The baby was uneventfully extubated on day 4 of life and transferred to ward on day 5 of life. The baby is now 9 months old and doing well in follow up. He has had no significant illness or hospitalisation since discharge from our hospital.

Discussion and evaluation {#Sec3}
=========================

The clinical picture in this case was suggestive of neonatal HUS, most likely attributable to birth asphyxia. Drastic falls in haemoglobin in absence of bleeding, as occurred in our neonate and fragmentocytes seen on the smear were suggestive of HUS. Serum haptoglobin levels and LDH are used as axillary tools in diagnosing intravascular hemolysis, but they are not reliable in a newborn due to inherent hepatic immaturity and these tests were not done in our case.

HUS needs to be differentiated from disseminated intravascular coagulation (DIC) and thrombotic thrombocytopenic purpura (TTP). There are no tests that can definitely differentiate HUS from DIC except that the coagulation profile is usually normal in HUS but it is abnormal in DIC. The fact that the child did not suffer any other MHA/TMA episode supports the idea that he does not have congenital TTP as the rate of recurrence is very high with congenital TTP; more than 60 % of patients have their relapses within the first year and about 90 % relapses within the first 4 years. (Hovinga et al. [@CR8]).

TTP can also present with similar symptomatology and associated thrombocytopenia, hyperbilirubinemia, increased creatinine, hemolysis etc. (Moake [@CR11]). Though rare, TTP is not as uncommon in infancy as previously thought. The congenital presentation of TTP is attributed to an inherent deficiency of vWF-cleaving metalloprotease (ADAMTS-13) (Moake [@CR11]). However, measurement of ADAMTS-13 in newborns is highly laboratory-dependent and also the fact that it is a costly investigation to obtain.

Non-immune thrombocytopenia in association with microangiopathic haemolytic anaemia can also occur in Kasabach Merritt syndrome and renal vein thrombosis. There was no suggestion of these in our neonate.

Three cases of neonatal HUS following asphyxia have been reported till date (Biran et al. [@CR2]). They also presented with a features of anaemia, thrombocytopenia and schistocytes on peripheral smear. Renal failure was present in all three cases. Two cases were treated with peritoneal dialysis while the other showed spontaneous improvement in renal parameters. The earliest onset was at 12 h. Biran et al. ([@CR2]) hypothesised that "endothelial damage that occurs in birth asphyxia leads to a vicious cycle of consumption of platelets and plasma factors involved in hemostasis and fibrinolysis (complement factors H/I and ADAMTS13)". Complement factor H/I deficiency is known to cause excessive activation of the alternative complement pathway causing injury to the capillary endothelial cells and subsequent symptoms of HUS (Caprioli et al. [@CR3]). ADAMTS13 is a metalloprotease enzyme which is needed to cleave the large multimers of vWF (von Willebrand factor) into smaller inert fractions. In the absence of this enzyme, the uncleaved large multimers induce platelet adhesion and aggregation at sites of endothelial injury leading to platelet rich thrombi in the end organs (Furlan and Lämmle [@CR7]). Besides consumption of these factors, congenital deficiency of ADAMTS can also precipitate HUS. We did not investigate for these deficiencies and it is possible that these deficiencies coexisted in our case.

Whatever the exact etiology of HUS in this case (whether secondary to alternate complement pathway activation or paucity of ADAMTS13) it responded dramatically to exchange transfusion (Licht et al. [@CR10]). Traditionally, transfusion of fresh frozen plasma (FFP) and plasmapheresis have been used in treatment of HUS irrespective of the exact etiopathogenesis (Scully et al. [@CR12]). Currently, the monoclonal antibody eculizumab is being used in some centres for the treatment of refractory TTP (Chapin et al. [@CR4]); Besbas et al. ([@CR1]) used this therapy successfully to treat an infant with recurrent disease. Treatment with eculizumab is expensive and takes time for its effects though. FFP acts by replacing the missing or altered complement factor H/I or ADAMTS13 enzyme. Plasmapheresis removes antibodies (which consume the ADAMTS13) as also the immune complexes and toxins but it is not useful in the congenital forms of HUS. An exchange transfusion combines both these functions of removing antibodies and replenishing the deficient or altered proteins (Coppo et al. [@CR5]). In the absence of facilities for plasmapheresis, exchange transfusion is a good alternative. Exchange transfusions are performed in most neonatal units usually in the context of neonatal hyperbilirubinemia. Neonatal HUS may be a new indication for this procedure.

Conclusions {#Sec4}
===========

Neonatal HUS is a very rare complication and even rarer associated with birth asphyxia. Early differentiation from similar presentation and diagnosis is important in terms of further planning and outcome. Exchange transfusion may be a viable alternative to plasmapheresis in resource limited settings.
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